A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Platelet function and the clinical course of the disease were prospectively investigated in 29 patients with myeloproliferative disorders. Serial determinations (median: 5 investigations per patient within 17 months) of platelet aggregation, plasma and intraplatelet concentrations of beta-thromboglobulin (beta TG) and platelet factor 4 (PF4), and of fibrinopeptide A (FPA) plasma levels were carried out. In the chronic phase of polycythaemia vera, patients with thrombohaemorrhagic complications during the study period had higher platelet count, more severe platelet aggregation defects, and increased plasma levels of beta TG and FPA compared to patients without complications. However, thrombohaemorrhagic complications were not predicted by changes in these parameters in the individual patient during the chronic disease phase. When patients with chronic myelogenous leukaemia entered blast crisis, bleeding complications were related to thrombocytopenia, impaired platelet function and low intraplatelet concentrations of beta TG and PF4. Cytoreduction by chemotherapy in the chronic phase of CML did not alter beta TG and PF4 plasma levels, whereas treatment of polycythaemia rubra vera by venesection favourably influenced platelet alpha-granule secretion and increased intraplatelet concentrations of beta TG and PF4.
Wehmeier
A
A
Department of Internal Medicine, University of Düsseldorf, Fed. Rep. Germany.
Fricke
S
S
Scharf
R E
RE
Schneider
W
W
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000502:physiology*; D005260:Female; D005344:Fibrinopeptide A / Q000378:metabolism; D006470:Hemorrhage / Q000097:blood / Q000150:complications; D006487:Hemostasis; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000150:complications; D010974:Platelet Aggregation; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000378:metabolism; D011087:Polycythemia Vera / Q000097:blood; D055728:Primary Myelofibrosis / Q000097:blood; D011446:Prospective Studies; D013920:Thrombocythemia, Essential / Q000097:blood; D013927:Thrombosis / Q000097:blood / Q000150:complications; D001620:beta-Thromboglobulin / Q000378:metabolism
D001620:beta-Thromboglobulin; D005344:Fibrinopeptide A; D010978:Platelet Factor 4